Article
Stapled peptide targeting the CDK4/Cyclin D interface combined with Abemaciclib inhibits KRAS mutant lung cancer growth.
Theranostics - 1 Jan 2020
Bouclier Celine, Simon Matthieu, Laconde Guillaume, Pellerano Morgan, Diot Sebastien, Lantuejoul Sylvie, Busser Benoit, Vanwonterghem Laetitia, Vollaire Julien, Josserand Véronique, Legrand Baptiste, Coll Jean-Luc, Amblard Muriel, Hurbin Amandine, Morris May C
Abstract excerpt
CDK4/cyclin D kinase constitutes an attractive pharmacological target for development of anticancer therapeutics, in particular in KRAS-mutant lung cancer patients, who have a poor prognosis and no targeted therapy available yet. Although several ATP-competitive inhibitors of CDK4 have been developed for anticancer therapeutics, they suffer from limited specificity and efficacy. Methods: As an alternative to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.